Partnership between Institut Curie and Harmonic Pharma
![Harmonic Pharma logo](/sites/techtransfer/files/styles/rectangle_grand_crop/public/medias/images/2017-08/HPH_Logo.jpg?h=49d301e8&itok=-4HssJSp)
As part of this partnership, Institut Curie will enable Harmonic Pharma to use the large collection of primary xenotransplants representative of human tumors of the Institut Curie explore the anti-cancer activity of several molecules in his portfolio.
Harmonic Pharma is a young innovative company whose main activity is to identify, through a molecular repositioning approach, new therapeutic uses for already known molecules.
"It is very important for us to rely on a major internationally recognized center such as the Institut Curie to access experimental models, know-how and basic knowledge on cancer development," said Michel Souchet, CEO of Harmonic Pharma.
"We quickly moved to three types of models for which we have a wide variety of tumors and a fairly long experience: breast cancers, lung cancers, and eye cancers," says Didier Decaudin, who heads the preclinical research laboratory of Institut Curie.
For this long-term collaboration, the costs will be shared between the two partners. Depending on the results obtained, some of the molecules studied can be taken over by Curie-Cancer for clinical studies for the benefit of patients.